Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
It has been shown in previous study that progressive glycemic deterioration was associated
with progressive loss of b-cell function, measured by the decrease in plasma insulin levels,
irrespective of the therapy used (diet, sulfonylureas or metformin).There is growing evidence
that thiazolidinediones could have a positive action on the b-cell function. But it has not
yet been demonstrated that they could protect from a deterioration in insulin secretion in
the long term. So, it appears interesting to study the long term evolution of the b-cell
function and the possible protection with rosiglitazone in patients with type 2 diabetes
showing evidence of loss of b-cell function with metformin alone.